Biogen To Submit Spinraza To UK's NICE For SMA, While Australia Wants More Data

 
• By Ian Schofield
  
Price - Value
Spinraza's cost effectiveness is being evaluated in the UK and Australia, among other countries.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet